On Wednesday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $53.76 which represents a slight increase of $0.86 or 1.63% from the prior close of $52.9. The stock opened at ...

FDA approves Bristol Myers' Opdivo for resectable non-small cell lung cancer, reducing recurrence risk by 42% and showing 70% 18-month event-free survival in patients.

With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be ...

A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?

(Bloomberg) -- Bristol Myers Squibb Co. raised its 2024 profit forecast as demand ... Bristol shares rose as much as 9.3% after US markets opened. The stock fell 12% this year through Thursday’s close ...

The pharmaceutical industry is promising due to AI and biotech innovations enhancing productivity, steady profits amidst ...

AbbVie's acquisition of Cerevel Therapeutics strengthens its neuroscience pipeline with promising candidates, making ABBV a ...

If we earn tomorrow’s dividend and then get assigned at expiration on October 25, we will earn $1.65 per share on $52.95 per ...

The approval came days before the FDA’s expected deadline and makes this the only PD-1 inhibitor approved for resectable ...

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...